Abstract: Described herein are example methods and systems for neuro-behavioral relationships in dimensional geometric bedding (N-BRIDGE), which includes a comprehensive, data-driven analytic framework for mapping the multi-dimensional relationships between neural and behavioral features in humans N-BRIDGE allows mapping of variations along newly-defined data-driven behavioral dimensions that capture the geometry of behavioral/symptom variation to variation in specific neural features.
Type:
Grant
Filed:
March 13, 2019
Date of Patent:
November 26, 2024
Assignee:
Yale University
Inventors:
Alan Anticevic, John Murray, Jie Lisa Ji
Abstract: The invention provides compositions and methods for binding and inhibiting renalase. In one embodiment, the renalase binding molecule inhibits renalase activity. Thus, in diseases and conditions where a reduction of renalase activity is beneficial, such inhibitory renalase binding molecules act as therapeutics.
Type:
Grant
Filed:
May 9, 2022
Date of Patent:
November 26, 2024
Assignee:
Yale University
Inventors:
Gary Desir, Abigail Hunt, Jessica O-Rear, Peter Flynn
Abstract: The present invention provides compositions and methods of preparing airway cells. In one aspect, an epithelial airway cell derived from an induced pluripotent stem (iPS) cell characterized by expression of airway cell surface markers and an ability to proliferate is described. In another aspect, methods of differentiating an iPS into an epithelial airway cell is provided. Engineered lungs, methods of making such engineered 10 lungs comprising the epithelial airway cells and treating respiratory disorders are also disclosed.
Abstract: The invention provides a system for hypothermic, restoration and preservation of organs in a mammal. In certain aspects, the system is capable of preserving organs, maintaining cellular integrity and cellular function for hours postmortem or after global ischemia. The invention also provides synthetic organ perfusate formulations, including a novel perfusate autologous blood mixture, which is able to reduce reperfusion injury, stimulate recovery from hypoxia, metabolically support the energy needs of organs and prevent rigor mortis.
Type:
Application
Filed:
September 16, 2022
Publication date:
November 14, 2024
Applicant:
Yale University
Inventors:
Nenad Sestan, Zvonnimir Vrselja, David Andrijevic
Abstract: The invention provides (1) processes for making substantially-pure (?) huperzine A and substantially-pure (?) huperzine A derivatives; (2) compositions useful in making substantially-pure (?) huperzine A and substantially-pure (?) huperzine A derivatives; and (3) methods of treating or preventing neurological disorders using substantially-pure (?) huperzine A and substantially-pure (?) huperzine A derivatives.
Abstract: In various aspects and embodiments the invention provides a method of treating pain, stress and anxiety in a subject in need thereof, wherein the method comprises administering to the subject in need thereof a pharmaceutical composition comprising cannabidiol (CBD) and tetrahydrocannabinol (THC) at a ratio between about 3:1 and about 6:1 CBD:THC.
Abstract: The present invention includes compositions and methods for treating diseases or disorders associated with pathological calcification or pathological ossification. In certain embodiments, the diseases or disorders are selected from the group consisting of Generalized Arterial Calcification of Infancy (GACI), Idiopathic Infantile Arterial Calcification (IIAC), Ossification of the Posterior Longitudinal Ligament (OPLL), hypophosphatemic rickets, osteoarthritis, calcification of atherosclerotic plaques, PXE, hereditary and non-hereditary forms of osteoarthritis, ankylosing spondylitis, hardening of the arteries occurring with aging, calciphylaxis resulting from end stage renal disease and progeria.
Abstract: The disclosure describes compounds of Formula Ia, which in non-limiting aspects contain an asialoglycoprotein receptor (ASGPR) binding moiety and an anti-?1AR binding moiety. Compounds of Formula Ia are useful in preventing, treating, and/or ameliorating heart failure in a subject when administered in therapeutically effective amounts.
Type:
Grant
Filed:
March 8, 2023
Date of Patent:
October 29, 2024
Assignee:
Yale University
Inventors:
David Caianiello, Edward Deramon, David Spiegel
Abstract: The invention includes a method of identifying a human subject at-risk of developing SeSAME syndrome. The invention also includes a method of diagnosing a human subject afflicted with SeSAME syndrome. The invention further includes a method of identifying a therapeutic agent that modulates a given KCNJ10 mediated K+ current in a mammalian cell. The invention also includes a method of diagnosing a subject as a carrier of SeSAME syndrome.
Abstract: The compounds of Formula I described herein regulate activity of JAK2 by specifically binding to the JAK2 pseudokinase domain, JH2, and are useful as therapeutic agents in the treatment or amelioration of myeloproliferative disorders. Also provided herein are methods of treating myeloproliferative disorders, and methods of making compounds of Formula I.
Type:
Grant
Filed:
October 13, 2021
Date of Patent:
October 8, 2024
Assignee:
Yale University
Inventors:
William L. Jorgensen, Joseph Schlessinger
Abstract: In one aspect the invention provides a method for distinguishing between a viral-only infection of the upper respiratory tract or a bacterial or viral/bacterial coinfection in a patient by analyzing a respiratory sample.
Abstract: The present invention relates to a system, device, and method for the high throughput multiplexed detection of a wide number of compounds. The invention comprises of a microwell array coupled to a capture agent array to form a plurality of interfaces between a microwell and a set of immobilized capture agents. The set of capture agents comprises a plurality of distinguishable features, with each feature corresponding to the detection of a particular compound of interest. In certain embodiments, each microwell is configured to contain a single cell. The invention is therefore capable of performing a high throughput analysis of single cell profiles, including profiles of secreted compounds.
Abstract: The present invention provides compositions and methods for treating diseases or disorders using a therapeutically effective amount of a rapid-acting antidepressant (RAAD) and a therapeutically effective amount of a mTOR inhibitor and/or immunosuppressant. In certain embodiments, the RAAD and the mTOR inhibitor and/or immunosuppressant are part of a single pharmaceutical composition.
Type:
Grant
Filed:
August 20, 2019
Date of Patent:
September 17, 2024
Assignees:
YALE UNIVERSITY, The United States Government as represented by the Department of Veterans Affairs
Inventors:
Chadi Abdallah, John Krystal, Ronald Duman, Gerard Sanacora
Abstract: The present invention provides compositions and methods for reducing inflammation. In one aspect, the present invention provides a protein inhibitor comprising an ectodomain of at least one TREM or TREML protein. The invention also relates to inhibiting the interaction between a TREM or TREML protein and mitochondria released or derived from necroptotic cells; or between a TREM or TREML protein and cardiolipin.
Abstract: Described herein is a bi-functional compound for removing macrophage migration inhibitory factor (MIF) or immunoglobulin G (IgG). Further described herein is a pharmaceutical composition which comprise these bi-functional compounds. Further described herein is a method for treating disease states and/or conditions with the compounds or the composition. The disease states and/or conditions are mediated through MIF/IgG or where MIF/IgG is a contributing factor to the development and perpetuation of diseases and/or conditions, such as autoimmune diseases and cancer, among others.
Abstract: The present disclosure relates, in part, to enhanced weathering systems and/or apparatuses and methods of use thereof. In one aspect, the present disclosure provides a method of at least partially sequestering CO2 from an influent aqueous solution comprising aqueous and/or gaseous CO2. In another aspect, the present disclosure provides a method of at least partially sequestering CO2 from a gaseous CO2 source. In another aspect, the present disclosure provides systems and/or apparatuses suitable for use in the methods described herein. In another aspect, the present disclosure provides a method of optimizing the design and operation of a system for at least partial sequestration of CO2 from a water source.
Type:
Grant
Filed:
April 10, 2023
Date of Patent:
September 10, 2024
Assignee:
YALE UNIVERSITY
Inventors:
Joachim Katchinoff, Noah Planavsky, Jacob Jordan, Dean Takahashi, Sinead Crotty, Justin Freiberg
Abstract: The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) through a linker and optionally, a connector molecule.
Type:
Grant
Filed:
June 7, 2023
Date of Patent:
September 10, 2024
Assignee:
YALE UNIVERSITY
Inventors:
David Spiegel, Ryan Murelli, Andrew Zhang
Abstract: In one aspect, the invention provides a protein capture membrane comprising a first side and a second side and a plurality of interstices extending contiguously from the first side to the second side, wherein the interstices are coated with a protein-reactive coating; and the porous substrate comprises nanoporous alumina or porous glass. In another aspect the invention provides a method of detecting a protein of interest in a plurality of proteins.
Type:
Grant
Filed:
May 7, 2019
Date of Patent:
September 10, 2024
Assignee:
Yale University
Inventors:
Erik Gunther, Mikhail Kostylev, Stephen Strittmatter
Abstract: The invention provides a system for normothermic, ex vivo restoration and preservation of an intact mammalian brain, and other organs. In certain aspects, the system is capable of preserving a brain as well as other organs, maintaining cellular integrity and cellular function for hours post mortem or after global ischemia. The invention also provides synthetic brain perfusate formulations, including a novel brain perfusion medium (BPM), which are able to reduce reperfusion injury, stimulate recovery from hypoxia, prevent edema and metabolically support the energy needs of brain function.
Type:
Application
Filed:
April 29, 2024
Publication date:
September 5, 2024
Applicant:
Yale University
Inventors:
Stefano Daniele, Nenad Sestan, John Silbereis, Zvonimir Vrselja
Abstract: Described herein are methods and compositions useful to reduce (partially/inhibit or completely—prevent) skin cancer development in an individual in need thereof.